ATE156361T1 - Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe - Google Patents

Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe

Info

Publication number
ATE156361T1
ATE156361T1 AT93920157T AT93920157T ATE156361T1 AT E156361 T1 ATE156361 T1 AT E156361T1 AT 93920157 T AT93920157 T AT 93920157T AT 93920157 T AT93920157 T AT 93920157T AT E156361 T1 ATE156361 T1 AT E156361T1
Authority
AT
Austria
Prior art keywords
protein
delayed release
medicinal products
contained medicinal
sustained
Prior art date
Application number
AT93920157T
Other languages
English (en)
Inventor
Michael J Hageman
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE156361T1 publication Critical patent/ATE156361T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT93920157T 1992-09-21 1993-08-23 Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe ATE156361T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94787292A 1992-09-21 1992-09-21
US96336592A 1992-10-20 1992-10-20

Publications (1)

Publication Number Publication Date
ATE156361T1 true ATE156361T1 (de) 1997-08-15

Family

ID=27130263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920157T ATE156361T1 (de) 1992-09-21 1993-08-23 Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe

Country Status (12)

Country Link
US (1) US6011011A (de)
EP (1) EP0661989B1 (de)
JP (2) JP3756512B2 (de)
AT (1) ATE156361T1 (de)
AU (1) AU5018693A (de)
DE (1) DE69312947T2 (de)
DK (1) DK0661989T3 (de)
ES (1) ES2107051T3 (de)
GR (1) GR3024632T3 (de)
MX (1) MX9305729A (de)
TW (1) TW224055B (de)
WO (1) WO1994006452A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150330A (en) 1996-01-11 2000-11-21 Pharmacia & Upjohn Company Aqueous prolonged release formulation
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
AU737664B2 (en) * 1996-07-03 2001-08-30 Alza Corporation Non-aqueous protic peptide formulations
KR100594519B1 (ko) * 1996-07-03 2007-03-02 앨자 코포레이션 비수성양성자성펩티드제제
KR100593221B1 (ko) * 1996-07-03 2007-03-02 알자 코포레이션 비수성극성비양성자성펩타이드제제
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
IN184589B (de) 1996-10-16 2000-09-09 Alza Corp
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6773711B2 (en) * 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6649161B1 (en) 2000-02-22 2003-11-18 Allergan, Inc. Method for treating hypocalcemia
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
EP1339312B1 (de) * 2000-10-10 2006-01-04 Microchips, Inc. Mikrochip-reservoir-vorrichtungen mit drahtloser übertragung von energie und daten
KR100838219B1 (ko) * 2001-07-13 2008-06-13 동아제약주식회사 인간성장호르몬의 지속적인 방출이 가능한 생분해성약학적 조성물 및 미립구 제형
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US7074425B2 (en) * 2002-09-26 2006-07-11 Bonewax, Llc Hemostatic compositions and methods
PT2891666T (pt) 2002-10-16 2017-09-22 Purdue Pharma Lp Anticorpos que se ligam ca 125/0722p associado a células e métodos para a sua utilização
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1663296A4 (de) * 2003-09-25 2009-11-25 Cangene Corp Flüssige menschliche wachstumshormonformulierung mit polyethylenglykol
EP1682537B1 (de) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulatoren der zellulären adhäsion
WO2006081279A2 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
TW200640492A (en) 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
CA2610159C (en) * 2005-06-10 2015-03-31 Altus Pharmaceuticals Inc. Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
PT2219603E (pt) 2007-11-02 2014-09-02 Acrux Dds Pty Ltd Piperazinas como agentes antimalariais
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
EP2276508A4 (de) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc Freisetzung von lfa-1-antagonisten gegen das magen-darm-system
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
DE102009056745A1 (de) * 2009-12-04 2011-06-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung von Peptiden
CN107056929A (zh) * 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
CN107674121A (zh) * 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
RU2768492C2 (ru) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
AR091784A1 (es) * 2012-07-17 2015-02-25 Bayer New Zealand Ltd Formaciones inyectables de antibiotico y sus metodos de aplicacion
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonisten der guanylatcyclase und deren verwendungen
US20160220630A1 (en) 2013-10-10 2016-08-04 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
CN113827704B (zh) * 2015-10-16 2024-07-12 瑞泽恩制药公司 稳定蛋白质组合物
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1185340A (en) * 1967-12-19 1970-03-25 Gen Foods Corp Water Dispersable Hydrophilic Colloid Composition.
US4041155A (en) * 1974-10-29 1977-08-09 American Home Products Corporation Long acting somatostatin composition
US3966962A (en) * 1975-03-27 1976-06-29 The Upjohn Company Triacetin solutions of PGE-type compounds
US4301175A (en) * 1980-12-29 1981-11-17 The Upjohn Company E-Type prostaglandin compositions
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
EP0140255B1 (de) * 1983-10-14 1991-05-15 Sumitomo Pharmaceuticals Company, Limited Injektionen mit verzögerter Abgabe
JPS60224638A (ja) * 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
ES8702440A1 (es) * 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
US4977140A (en) * 1985-08-23 1990-12-11 Eli Lilly And Company Injectable sustained release formulation
JPS62123112A (ja) * 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
FR2606597B1 (fr) * 1986-11-17 1989-01-27 Rhone Poulenc Sante Nouvelle composition pour l'alimentation des ruminants contenant une substance biologiquement active et sa preparation
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5004728A (en) * 1988-03-11 1991-04-02 The Trustees Of The University Of Pennsylvania Methods of increasing milk yields in ruminants
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
DE59009781D1 (de) * 1989-05-16 1995-11-23 Puetter Medice Chem Pharm Verfahren zur Herstellung optisch aktiver 2-Aryl-Alkansäuren, insbesondere von 2-Aryl-Propionsäuren.
NZ234802A (en) * 1989-08-14 1992-11-25 Merck & Co Inc Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
US5179189A (en) * 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
EP0532546B1 (de) * 1990-05-10 1998-03-18 Bechgaard International Research And Development A/S Pharmazeutische zubereitung enthaltend n-glykofurole und n-äthylenglykole
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments

Also Published As

Publication number Publication date
EP0661989B1 (de) 1997-08-06
DK0661989T3 (da) 1998-03-02
TW224055B (de) 1994-05-21
JP3756512B2 (ja) 2006-03-15
JPH08501305A (ja) 1996-02-13
JP2004285079A (ja) 2004-10-14
AU5018693A (en) 1994-04-12
MX9305729A (es) 1994-03-31
EP0661989A1 (de) 1995-07-12
ES2107051T3 (es) 1997-11-16
US6011011A (en) 2000-01-04
WO1994006452A1 (en) 1994-03-31
GR3024632T3 (en) 1997-12-31
DE69312947D1 (de) 1997-09-11
DE69312947T2 (de) 1998-01-08

Similar Documents

Publication Publication Date Title
ATE156361T1 (de) Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
AU6819294A (en) Oral drug delivery compositions and methods
HK1021824A1 (en) Compositions and methods for treating infections using analogues of indolicidin
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
EP1686172A3 (de) Herztransplantate und dafür nützliche Zellzusammensetzungen
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
CA2045869A1 (en) Fusion proteins with immunoglobulin portions, the preparation and use thereof
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
EP0422125A4 (en) Platelet blocking peptides
EA200000685A1 (ru) Комплекс ifnar2/ifn
ATE225806T1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
CA2071757A1 (en) Implant compositions containing a biologically active protein, peptide or polypeptide
AU3629389A (en) Novel peptides suppressing the function of the immune system, pharmaceutical compositions containing them and process for preparing same
EP1174439A3 (de) Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
CA2163805A1 (en) Novel activating factor of leukocytes
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee